Takeda (ADR) (TAK)
Develops prescription medicines across gastrointestinal disease, rare disease, plasma therapies, oncology, neuroscience, and vaccines.
$19.02
vs last close+0.13 (+0.66%)
In millions of USD, except per-share figures · converted from JPY at the latest rate
| In millions | Q2 FY23Sep 2023 | Q3 FY23Dec 2023 | Q4 FY23Mar 2024 | Q1 FY24Jun 2024 | Q2 FY24Sep 2024 | Q3 FY24Dec 2024 | Q4 FY24Mar 2025 | Q1 FY25Jun 2025 | Q2 FY25Sep 2025 | Q3 FY25Dec 2025 | Q4 FY25Mar 2026 | Q1 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,627 | 7,059 | 6,676 | 7,674 | 7,471 | 7,269 | 6,692 | 7,031 | 7,070 | 7,708 | 7,081 | 7,750 |
| Cost of revenue | 2,183 | 2,411 | 2,461 | 2,458 | 2,505 | 2,648 | 2,427 | 2,444 | 2,415 | 3,512 | 3,627 | 2,584 |
| Gross profit | 4,444 | 4,649 | 4,216 | 5,216 | 4,966 | 4,620 | 4,265 | 4,587 | 4,655 | 4,195 | 3,455 | 5,166 |
| 4,757 | 3,982 | 4,279 | 4,159 | 3,796 | 4,195 | 4,741 | 3,414 | 4,217 | 2,962 | 3,153 | 3,887 | |
| Research & development | 1,169 | 1,190 | 1,244 | 1,070 | 1,115 | 1,081 | 1,372 | 914 | 1,026 | 1,133 | 1,264 | 1,063 |
| Selling, general & administrative | 1,607 | 1,700 | 1,812 | 1,716 | 1,704 | 1,719 | 1,880 | 1,626 | 1,611 | 1,829 | 1,889 | 1,820 |
| Other expenses | 1,982 | 1,092 | 1,223 | 1,374 | 976 | 1,395 | 1,489 | 875 | 1,580 | 0 | 0 | 1,003 |
| Operating income | −313 | 667 | −64 | 1,057 | 1,171 | 425 | −476 | 1,173 | 438 | 1,233 | 302 | 1,280 |
| −296 | −277 | −238 | −189 | −412 | −258 | −206 | −216 | −259 | −367 | −642 | −246 | |
| Interest income | 0 | 138 | 0 | 195 | 26 | 0 | 1 | 469 | 282 | 568 | 33 | 156 |
| Interest expense | 3 | 423 | 2 | 379 | 435 | 1 | 2 | 681 | 528 | 800 | 282 | 406 |
| Other non-operating income | −72 | 222 | −1,055 | −190 | −23 | 387 | −422 | −465 | −269 | −432 | 359 | −160 |
| Income before tax | −610 | 389 | −302 | 868 | 758 | 168 | −682 | 957 | 179 | 866 | −340 | 1,034 |
| Income tax expense | −305 | −283 | −283 | 262 | 173 | 16 | −27 | 167 | 254 | 195 | −183 | 314 |
| Net income from continuing operations | −305 | 672 | −19 | 605 | 585 | 151 | −655 | 790 | −75 | 671 | −157 | 720 |
| Discontinued operations | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other adjustments | 0 | 0 | 0 | 0 | −3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −305 | 672 | −19 | 605 | 585 | 151 | −656 | 789 | −75 | 670 | −157 | 719 |
| EPS, basic | −$0.10 | $0.21 | −$0.01 | $0.19 | $0.18 | $0.05 | −$0.21 | $0.25 | −$0.02 | $0.21 | −$0.05 | $0.23 |
| EPS, diluted | −$0.10 | $0.21 | −$0.01 | $0.19 | $0.18 | $0.05 | −$0.21 | $0.25 | −$0.02 | $0.21 | −$0.05 | $0.22 |
| Weighted average shares, basic | 3,131 | 3,138 | 3,137 | 3,138 | 3,166 | 3,170 | 3,163 | 3,129 | 3,155 | 3,159 | 3,125 | 3,160 |
| Weighted average shares, diluted | 3,131 | 3,170 | 3,137 | 3,178 | 3,220 | 3,170 | 3,163 | 3,176 | 3,155 | 3,205 | 3,125 | 3,209 |
| EBITDA | 1,285 | 1,633 | 1,647 | 2,468 | 2,416 | 1,226 | 1,152 | 2,792 | 2,011 | 2,898 | 1,003 | 2,144 |
| Depreciation & amortization | 1,526 | 1,188 | 656 | 1,221 | 1,223 | 1,188 | 1,206 | 1,154 | 1,303 | 1,233 | 1,060 | 705 |
| EBIT | −241 | 444 | 991 | 1,247 | 1,193 | 38 | −54 | 1,638 | 707 | 1,665 | −57 | 1,439 |